EVEREST-1: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod Chimeric Antigen Receptor T Cell (CAR T) in Heterozygous HLA-A*02 Adult Subjects with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Or Metastatic Solid Tumors
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. Has tissue that shows a specific genetic marker called LOH of HLA-A*02:01 by NGS, and have undergone a successful apheresis and PBMC processing, and there are enough cells stored for the Tmod therapy.
    2. Cancer has spread and cannot be removed by surgery, or it is located in a hard-to-reach place. The cancer may be in the colon or rectum, lungs, pancreas, or other parts of the body, and it is associated with a protein called CEA.
    3. Cannot have or doesn't want other common treatments for their condition.

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have:
    1. Illness that can be treated locally (in a specific part of the body) or with a standard medical treatment that can cure the disease and is not just meant to relieve symptoms.
    2. Any cancer other than nonmelanoma skin cancer, low grade prostate cancer that hasn't spread, bladder cancer that hasn't spread, early-stage breast or cervical cancer, or stage 1 uterine cancer in the past.
    3. Received a type of medical treatment called an allogeneic stem cell transplant in the past.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.